Core Viewpoint - The company has received approval from the National Medical Products Administration of China for its quadrivalent influenza virus subunit vaccine, making it the first and only approved vaccine of its kind for the entire population in China [1] Company Overview - The company is a vaccine manufacturer based in China, focusing on the research, development, manufacturing, and commercialization of innovative vaccines and traditional vaccines using new technologies [1] - The company aims to replace traditional and imported vaccines in China with high-quality vaccines and expand its competitive advantages to international markets [1] Product Details - The newly approved quadrivalent influenza virus subunit vaccine is designed for individuals aged 6 to 35 months and offers comprehensive protection, high purity of antigen components, and a low risk of adverse reactions [1] - The product represents a significant upgrade over traditional virus-inactivated vaccines [1] - The company's product pipeline includes the quadrivalent influenza virus subunit vaccine, a lyophilized human rabies vaccine under development, and other vaccines in the research phase [1]
中慧生物-B：四价流感病毒亚单位疫苗的上市申请获国家药监局批准